Ultrasound Molecular Imaging: Moving Toward Clinical Translation

Overview

Journal Eur J Radiol

Specialty Radiology

Date 2015 Apr 9

PMID 25851932

Citations 83

Authors

Lotfi Abou-Elkacem

Sunitha V Bachawal

Jurgen K Willmann

Affiliations

Soon will be listed here.

Abstract

Ultrasound is a widely available, cost-effective, real-time, non-invasive and safe imaging modality widely used in the clinic for anatomical and functional imaging. With the introduction of novel molecularly-targeted ultrasound contrast agents, another dimension of ultrasound has become a reality: diagnosing and monitoring pathological processes at the molecular level. Most commonly used ultrasound molecular imaging contrast agents are micron sized, gas-containing microbubbles functionalized to recognize and attach to molecules expressed on inflamed or angiogenic vascular endothelial cells. There are several potential clinical applications currently being explored including earlier detection, molecular profiling, and monitoring of cancer, as well as visualization of ischemic memory in transient myocardial ischemia, monitoring of disease activity in inflammatory bowel disease, and assessment of arteriosclerosis. Recently, a first clinical grade ultrasound contrast agent (BR55), targeted at a molecule expressed in neoangiogenesis (vascular endothelial growth factor receptor type 2; VEGFR2) has been introduced and safety and feasibility of VEGFR2-targeted ultrasound imaging is being explored in first inhuman clinical trials in various cancer types. This review describes the design of ultrasound molecular imaging contrast agents, imaging techniques, and potential future clinical applications of ultrasound molecular imaging.

Citing Articles

Quantifying Molecular Changes in the Preeclamptic Rat Placenta with Targeted Contrast-Enhanced Ultrasound Imaging.

Shi L, Alencar A, Swan K, Lawrence D, Pridjian G, Bayer C Mol Imaging Biol. 2025; .

PMID: 40014198 DOI: 10.1007/s11307-025-01988-4.

Predictive nomogram of ultrasound indicators for the termination outcome of caesarean scar pregnancy.

Xiao X, Feng Z, Li T, Qiao H, Zhu Y Sci Rep. 2024; 14(1):31378.

PMID: 39733108 PMC: 11682213. DOI: 10.1038/s41598-024-82894-7.

Ultrasound Molecular Imaging Enhances High-Intensity Focused Ultrasound Ablation on Liver Cancer With B7-H3-Targeted Microbubbles.

Xiong X, Zhou H, Xu X, Fu Q, Wan Y, Cao Y Cancer Med. 2024; 13(20):e70341.

PMID: 39431644 PMC: 11492419. DOI: 10.1002/cam4.70341.

Nanotechnology based gas delivery system: a "green" strategy for cancer diagnosis and treatment.

Chen M, Xu T, Song L, Sun T, Xu Z, Zhao Y Theranostics. 2024; 14(14):5461-5491.

PMID: 39310098 PMC: 11413789. DOI: 10.7150/thno.98884.

The Current Status and Future Directions on Nanoparticles for Tumor Molecular Imaging.

Yin C, Hu P, Qin L, Wang Z, Zhao H Int J Nanomedicine. 2024; 19:9549-9574.

PMID: 39296941 PMC: 11409933. DOI: 10.2147/IJN.S484206.

References

Chadderdon S, Belcik J, Bader L, Kirigiti M, Peters D, Kievit P . Proinflammatory endothelial activation detected by molecular imaging in obese nonhuman primates coincides with onset of insulin resistance and progressively increases with duration of insulin resistance. Circulation. 2013; 129(4):471-8. PMC: 3909516. DOI: 10.1161/CIRCULATIONAHA.113.003645. View

Willmann J, Paulmurugan R, Chen K, Gheysens O, Rodriguez-Porcel M, Lutz A . US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology. 2008; 246(2):508-18. PMC: 4157631. DOI: 10.1148/radiol.2462070536. View

Warram J, Sorace A, Saini R, Umphrey H, Zinn K, Hoyt K . A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature. J Ultrasound Med. 2011; 30(7):921-31. PMC: 3140433. DOI: 10.7863/jum.2011.30.7.921. View

Wang H, Kaneko O, Tian L, Hristov D, Willmann J . Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer. Invest Radiol. 2015; 50(5):322-9. PMC: 4470566. DOI: 10.1097/RLI.0000000000000128. View

Deshpande N, Needles A, Willmann J . Molecular ultrasound imaging: current status and future directions. Clin Radiol. 2010; 65(7):567-81. PMC: 3144865. DOI: 10.1016/j.crad.2010.02.013. View

Inaba Y, Lindner J . Molecular imaging of disease with targeted contrast ultrasound imaging. Transl Res. 2012; 159(3):140-8. PMC: 3285422. DOI: 10.1016/j.trsl.2011.12.001. View

Lutz A, Bachawal S, Drescher C, Pysz M, Willmann J, Gambhir S . Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model. Clin Cancer Res. 2014; 20(5):1313-22. PMC: 3965293. DOI: 10.1158/1078-0432.CCR-13-1642. View

Khanicheh E, Qi Y, Xie A, Mitterhuber M, Xu L, Mochizuki M . Molecular imaging reveals rapid reduction of endothelial activation in early atherosclerosis with apocynin independent of antioxidative properties. Arterioscler Thromb Vasc Biol. 2013; 33(9):2187-92. PMC: 3888901. DOI: 10.1161/ATVBAHA.113.301710. View

Hyvelin J, Tardy I, Bettinger T, von Wronski M, Costa M, Emmel P . Ultrasound molecular imaging of transient acute myocardial ischemia with a clinically translatable P- and E-selectin targeted contrast agent: correlation with the expression of selectins. Invest Radiol. 2014; 49(4):224-35. DOI: 10.1097/RLI.0000000000000018. View

10.

Tardy I, Pochon S, Theraulaz M, Emmel P, Passantino L, Tranquart F . Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Invest Radiol. 2010; 45(10):573-8. DOI: 10.1097/RLI.0b013e3181ee8b83. View

11.

Frinking P, Tardy I, Theraulaz M, Arditi M, Powers J, Pochon S . Effects of acoustic radiation force on the binding efficiency of BR55, a VEGFR2-specific ultrasound contrast agent. Ultrasound Med Biol. 2012; 38(8):1460-9. DOI: 10.1016/j.ultrasmedbio.2012.03.018. View

12.

Wang H, Felt S, Machtaler S, Guracar I, Luong R, Bettinger T . Quantitative Assessment of Inflammation in a Porcine Acute Terminal Ileitis Model: US with a Molecularly Targeted Contrast Agent. Radiology. 2015; 276(3):809-17. PMC: 4557395. DOI: 10.1148/radiol.2015142478. View

13.

Wei K, Main M, Lang R, Klein A, Angeli S, Panetta C . The effect of Definity on systemic and pulmonary hemodynamics in patients. J Am Soc Echocardiogr. 2012; 25(5):584-8. DOI: 10.1016/j.echo.2012.01.019. View

14.

Kaufmann B, Lewis C, Xie A, Mirza-Mohd A, Lindner J . Detection of recent myocardial ischaemia by molecular imaging of P-selectin with targeted contrast echocardiography. Eur Heart J. 2007; 28(16):2011-7. DOI: 10.1093/eurheartj/ehm176. View

15.

Walday P, Tolleshaug H, Gjoen T, Kindberg G, Berg T, Skotland T . Biodistributions of air-filled albumin microspheres in rats and pigs. Biochem J. 1994; 299 ( Pt 2):437-43. PMC: 1138291. DOI: 10.1042/bj2990437. View

16.

Pysz M, Willmann J . Targeted contrast-enhanced ultrasound: an emerging technology in abdominal and pelvic imaging. Gastroenterology. 2011; 140(3):785-90. PMC: 4162392. DOI: 10.1053/j.gastro.2011.01.027. View

17.

Hamilton A, Huang S, Warnick D, Rabbat M, Kane B, Nagaraj A . Intravascular ultrasound molecular imaging of atheroma components in vivo. J Am Coll Cardiol. 2004; 43(3):453-60. DOI: 10.1016/j.jacc.2003.07.048. View

18.

Deshpande N, Lutz A, Ren Y, Foygel K, Tian L, Schneider M . Quantification and monitoring of inflammation in murine inflammatory bowel disease with targeted contrast-enhanced US. Radiology. 2011; 262(1):172-80. PMC: 3244669. DOI: 10.1148/radiol.11110323. View

19.

Leguerney I, Scoazec J, Gadot N, Robin N, Penault-Llorca F, Victorin S . Molecular ultrasound imaging using contrast agents targeting endoglin, vascular endothelial growth factor receptor 2 and integrin. Ultrasound Med Biol. 2014; 41(1):197-207. DOI: 10.1016/j.ultrasmedbio.2014.06.014. View

20.

Bachmann C, Klibanov A, Olson T, Sonnenschein J, Rivera-Nieves J, Cominelli F . Targeting mucosal addressin cellular adhesion molecule (MAdCAM)-1 to noninvasively image experimental Crohn's disease. Gastroenterology. 2006; 130(1):8-16. DOI: 10.1053/j.gastro.2005.11.009. View